Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018

Drug Resistance Updates

Volumn 37, Issue , 2018, Pages 17-39

  Sorbo, Maria C ^a   Cento, Valeria ^d   Di Maio, Velia C ^a   Howe, Anita Y M ^b   Garcia, Federico ^c   Perno, Carlo F ^d   Ceccherini Silberstein, Francesca ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b ST PAUL S HOSPITAL   (Canada)

^c HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Direct acting antiviral agents; Fold change; HCV genotypic resistance testing; HCV sequencing; Treatment failure

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; DACLATASVIR; DASABUVIR; DIRECT ACTING ANTIVIRUS AGENT; ELBASVIR; GLECAPREVIR; GRAZOPREVIR; LEDIPASVIR; NONSTRUCTURAL PROTEIN 5A INHIBITOR; NONSTRUCTURAL PROTEIN 5B; OMBITASVIR; PARITAPREVIR; PIBRENTASVIR; PROTEINASE INHIBITOR; RNA DIRECTED RNA POLYMERASE INHIBITOR; SIMEPREVIR; SOFOSBUVIR; UNCLASSIFIED DRUG; VANIPREVIR; VELPATASVIR; VOXILAPREVIR; NS-5 PROTEIN, HEPATITIS C VIRUS; NS3 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

CLINICAL PRACTICE; DRUG CONFORMATION; DRUG SENSITIVITY; HEPATITIS C; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; REPLICON; RESISTANCE ASSOCIATED SUBSTITUTION; RETREATMENT; REVIEW; SYSTEMATIC REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; CHRONIC HEPATITIS C; DRUG DESIGN; DRUG EFFECT; GENETICS; GENOTYPE; HEPACIVIRUS; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; TREATMENT FAILURE; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; DRUG DESIGN; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; TREATMENT FAILURE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 85042923997     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2018.01.004     Document Type: Review

References (182)

1. AASLD-IDSA, Recommendations for Testing, Managing, and Treating Hepatitis C. 2018 (http://www.hcvguidelines.org. Accessed 24 October 2017).
2. Abergel, A., Metivier, S., Samuel, D., et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology, 2016.
3. Afdhal, N., Zeuzem, S., Kwo, P., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 370:20 (2014), 1889–1898.
4. Ali, A., Aydin, C., Gildemeister, R., et al. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. ACS Chem. Biol. 8:7 (2013), 1469–1478.
5. Andreone, P., Colombo, M.G., Enejosa, J.V., et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 147:2 (2014), 59–65 (e1).
6. Asante-Appiah, E., Marshall, W., Gane, E., et al. In a 5-day monotherapy trial, MK-8408 demonstrated potent antiviral activity and improved resistance profile in HCV patients with genotypes 1, 2, and 3 infections [Abstract THU-222]. The International Liver Congress™ 2016, EASL – European Association for the Study of the Liver, Barcelona, Spain, 2016 (Journal of Hepatology).
7. Asante-Appiah, E., Curry, S., McMonagle, P., et al. Antiviral activity and resistance analysis of NS3/4A protease inhibitor grazoprevir and NS5A inhibitor elbasvir in hepatitis C virus GT4 replicons. Antimicrob. Agents Chemother., 61, 2017, 7.
8. Bae, A., Sun, S.C., Qi, X., et al. Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob. Agents Chemother. 54:12 (2010), 5288–5297.
9. Barnard, R.J., McHale, C.M., Newhard, W., et al. Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis. Virology 443:2 (2013), 278–284.
10. Bartenschlager, R., Lohmann, V., Penin, F., The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat. Rev. Microbiol. 11:7 (2013), 482–496.
11. Bilello, J.P., Lallos, L.B., McCarville, J.F., et al. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus. Antimicrob. Agents Chemother. 58:8 (2014), 4431–4442.
12. Black, S., Pak, I., Ingravallo, P., et al. Resistance analysis of virologic failures in hepatitis c genotype 1-Infected patients treated with Grazoprevir + Elbasvir ± Ribavirin: the C-WORTHY study [Abstract P0891]. The International Liver Congress™ 2015, EASL – European Association for the Study of the Liver, Vienna, Austria, 2015, S677–S678 (Journal of Hepatology).
13. Bukh, J., The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. J. Hepatol. 65:1 Suppl (2016), S2–S21.
14. Buti, M., Gordon, S.C., Zuckerman, E., et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis c virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE. Clin. Infect. Dis. 62:1 (2016), 32–36.
15. Cento, V., Mirabelli, C., Salpini, R., et al. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS One, 7(7), 2012, e39652.
16. Charlton, M., Manns, M., Dvory-Sobol, H., et al. Resistance analyses for ledipasvir/sofosbuvir-containing regimens in patients infected with chronic HCV who have advanced liver disease or are post liver transplant (SOLAR-1 and -2 studies). The International Liver Congress™ 2016, EASL – European Association for the Study of the Liver, Barcelona, Spain, 2016.
17. Coburn, C.A., Meinke, P.T., Chang, W., et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem 8:12 (2013), 1930–1940.
18. Curry, M.P., O'Leary, J.G., Bzowej, N., et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N. Engl. J. Med. 373:27 (2015), 2618–2628.
19. Curtis, L.C., N, S., Saag, M., Yang, J.C., Stamm, L.M., Dvory-Sobol, H., Pang, P.S., McHutchison, J.G., Dieterich, D., Sulkowski, M., Retreatment of HCV/HIV-Coinfected patients who failed 12 weeks of LDV/SOF [Poster #573]. Conference on Retroviruses and Opportunistic Infections (CROI), 2016, Boston, 2016.
20. DeGoey, D.A., Randolph, J.T., Liu, D., et al. Discovery of ABT-267: a pan-genotypic inhibitor of HCV NS5A. J. Med. Chem. 57:5 (2014), 2047–2057.
21. Di Maio, V.C., Cento, V., Lenci, I., et al. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 37:4 (2017), 514–528.
22. Dietz, J., Susser, S., Vermehren, J., et al. Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals. Gastroenterology, 2017.
23. Dietz, J., Vermehren, J., Susser, S., et al. Resistance patterns in patients with chronic hepatitis C genotype 4 infection and treatment outcome [Abstract FRI-258]. The International Liver Congress™ 2017, EASL – European Association for the Study of the Liver, Amsterdam, The Netherlands, 2017, S525 (Journal of Hepatology).
24. ®2017, AASLD – American Association for the Study of Liver Diseases, Washington, DC, 2017 (Hepatology).
25. ®2013, AASLD – American Association for the Study of Liver Diseases, Washington, 2013 (Hepatology).
26. Donaldson, E.F., Harrington, P.R., O'Rear, J.J., Naeger, L.K., Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 61:1 (2015), 56–65.
27. Dore, G.J., Lawitz, E., Hezode, C., et al. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology 148:2 (2015), 355–366 (e1).
28. Dvory-Sobol, H., Doehle, B., Svarovskaia, E., et al. The prevalence of HCV NS5A nucleoside and protease inhibitor resistance associated variants and the effects on treatment with ledipasvir/sofosbuvir+ RBV in the phase 3 ION study. International Workshop on Antiviral Drug Resistance, Berlin, German, 2014.
29. ®2017, AASLD – American Association for the Study of Liver Diseases, Washington, DC, 2017 (Hepatology).
30. EASL, Recommendations on Treatment of Hepatitis C 2016, Update of September 2016., 2017 (Available at: http://www.easl.eu/medias/cpg/HCV2016/English-report.pdf. Accessed 24 September 2017).
31. Everson, G.T., Sims, K.D., Rodriguez-Torres, M., et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 146:2 (2014), 420–429.
32. Feld, J.J., Kowdley, K.V., Coakley, E., et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 370:17 (2014), 1594–1603.
33. Feld, J.J., Jacobson, I.M., Hezode, C., et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N. Engl. J. Med. 373:27 (2015), 2599–2607.
34. Ferenci, P., Bernstein, D., Lalezari, J., et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N. Engl. J. Med. 370:21 (2014), 1983–1992.
35. Fevery, B., Thys, K., Van Eygen, V., et al. Pre-existence and persistence of resistant minority hepatitis C virus variants in genotype 1-infected patients treated with Simeprevir/Peginterferon/Ribavirin. Open Forum Infect. Dis., 3(2), 2016, ofw52.
36. Forns, X., Lawitz, E., Zeuzem, S., et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 146:7 (2014), 1669–1679 (e3).
37. Forns, X., Gordon, S.C., Zuckerman, E., et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J. Hepatol. 63:3 (2015), 564–572.
38. Foster, G.R., Afdhal, N., Roberts, S.K., et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N. Engl. J. Med. 373:27 (2015), 2608–2617.
39. ®2016, AASLD – American Association for the Study of Liver Diseases, Boston (MA), 2016 (Hepatology).
40. Friborg, J., Zhou, N., Han, Z., et al. In vitro assessment of re-treatment options for patients with hepatitis C virus genotype 1b infection resistant to daclatasvir plus asunaprevir. Infect. Dis. Therapy, 2014.
41. Fridell, R.A., Qiu, D., Wang, C., Valera, L., Gao, M., Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother. 54:9 (2010), 3641–3650.
42. Fridell, R.A., Qiu, D., Valera, L., Wang, C., Rose, R.E., Gao, M., Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J. Virol. 85:14 (2011), 7312–7320.
43. Fridell, R.A., Wang, C., Sun, J.H., et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 54:6 (2011), 1924–1935.
44. Fried, M.W., Buti, M., Dore, G.J., et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 58:6 (2013), 1918–1929.
45. Gane, E.J., Stedman, C.A., Hyland, R.H., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368:1 (2013), 34–44.
46. ®2015, AASLD – American Association for the Study of Liver Diseases, San Francisco, CA, 2015, 322A (Hepatology).
47. ®2015, AASLD – American Association for the Study of Liver Diseases, San Francisco, 2015 (Hepatology).
48. Gane, E.J., Schwabe, C., Hyland, R.H., et al. Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3/4A protease inhibitor GS-9857 in treatment-naive or previously treated patients with HCV genotype 1 or 3 infections. Gastroenterology, 2016.
49. Gao, M., Nettles, R.E., Belema, M., et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:7294 (2010), 96–100.
50. Harper, S., McCauley, J.A., Rudd, M.T., et al. Discovery of MK-5172: a macrocyclic hepatitis C virus NS3/4a protease inhibitor. ACS Med. Chem. Lett. 3:4 (2012), 332–336.
51. Harrington, P.R., Komatsu, T.E., Deming, D.J., Donaldson, E.F., O'Rear, J.J., Naeger, L.K., Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: regulatory analyses and perspectives. Hepatology, 2017.
52. Hayashi, N., Seto, C., Kato, M., Komada, Y., Goto, S., Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J. Gastroenterol. 49:1 (2014), 138–147.
53. Hayashi, N., Nakamuta, M., Takehara, T., et al. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study. J. Gastroenterol. 51:4 (2016), 390–403.
54. Hernandez, D., Zhou, N., Ueland, J., Monikowski, A., McPhee, F., Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J. Clin. Virol. 57:1 (2013), 13–18.
55. Hezode, C., Asselah, T., Reddy, K.R., et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 385:9986 (2015), 2502–2509.
56. Hezode, C., Colombo, M., Spengler, U., et al. C-EDGE IBLD: efficacy and safety of Elbasvir/Grazoprevir in patients with chronic hepatitis C virus infection and inherited blood disorders [Abstract SAT-128]. The International Liver Congress™ 2016, EASL – European Association for the Study of the Liver, Barcelona, 2016, S753 (Journal of Hepatology).
57. Hezode, C., Chevaliez, S., Scoazec, G., et al. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen. Hepatology 63:6 (2016), 1809–1816.
58. Howe, A.Y., Black, S., Curry, S., et al. Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Clin. Infect. Dis. 59:12 (2014), 1657–1665.
59. Huang, W., Newton, A., Frantzell, A., et al. Genotypic and phenotypic characterization of clinical HCV NS5A drug resistance [Abstract 579]. Conference on Retroviruses and Opportunistic Infections (CROI), 2016, Boston, 2016.
60. Iio, E., Shimada, N., Abe, H., et al. Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1. J. Gastroenterol., 2016.
61. Izumi, N., Hayashi, N., Kumada, H., et al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J. Gastroenterol. 49:5 (2014), 941–953.
62. JSH, JSH Guidelines for the Management of Hepatitis C Virus Infection: a Update for Genotype 1. 2014 (Accessed 21 July 2016).
63. ®2015, AASLD – American Association for the Study of Liver Diseases, San Francisco, 2015 (Hepatology).
64. Jacobson, I.M., Lawitz, E., Kwo, P.Y., et al. Safety and efficacy of Elbasvir/Grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis: an integrated analysis. Gastroenterology, 2017.
65. Jensen, S.B., Serre, S.B., Humes, D.G., et al. Substitutions at NS3 Residue 155: 156, or 168 of Hepatitis C Virus Genotypes 2–6 Induce Complex Patterns of Protease Inhibitor Resistance. Antimicrob. Agents Chemother. 59:12 (2015), 7426–7436.
66. Jensen, D., Sherman, K.E., Hezode, C., et al. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. J. Hepatol. 63:1 (2015), 30–37.
67. Jiang, M., Mani, N., Lin, C., et al. In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir. Antimicrob. Agents Chemother. 57:12 (2013), 6236–6245.
68. Kalaghatgi, P., Sikorski, A.M., Knops, E., et al. Geno2pheno[HCV] – a web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents. PLoS One, 11(5), 2016, e0155869.
69. Kanda, T., Yasui, S., Nakamura, M., et al. Daclatasvir plus asunaprevir treatment for real-world HCV genotype 1-infected patients in Japan. Int. J. Med. Sci. 13:6 (2016), 418–423.
70. Kanwal, F., Kramer, J.R., Ilyas, J., Duan, Z., El-Serag, H.B., HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology 60:1 (2014), 98–105.
71. Karino, Y., Toyota, J., Ikeda, K., et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J. Hepatol. 58:4 (2013), 646–654.
72. Kati, W., Koev, G., Irvin, M., et al. In vitro activity and resistance profile of dasabuvir: a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob. Agents Chemother. 59:3 (2015), 1505–1511.
73. Kieffer, T.L., George, S., Resistance to hepatitis C virus protease inhibitors. Curr. Opin. Virol. 8 (2014), 16–21.
74. Komatsu, T.E., Boyd, S., Sherwat, A., et al. Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of Elbasvir and Grazoprevir. Gastroenterology 152:3 (2017), 586–597.
75. Kowdley, K.V., Gordon, S.C., Reddy, K.R., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 370:20 (2014), 1879–1888.
76. Krishnan, P., Tripathi, R., Schnell, G., et al. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob. Agents Chemother. 59:9 (2015), 5445–5454.
77. Krishnan, P., Beyer, J., Mistry, N., et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir: an inhibitor of hepatitis C virus NS5A. Antimicrob. Agents Chemother. 59:2 (2015), 979–987.
78. Krishnan, P., Schnell, G., Tripathi, R., et al. Analysis of hepatitis C virus genotype 1b resistance variants in Japanese patients treated with paritaprevir-ritonavir and ombitasvir. Antimicrob. Agents Chemother. 60:2 (2016), 1106–1113.
79. Krishnan, P., Schnell, G., Tripathi, R., et al. Pooled resistance analysis in HCV genotype 1–6-infected patients treated with glecaprevir/pibrentasvir in phase 2 and 3 clinical trials [Abstract FRI-205]. The International Liver Congress™ 2017, EASL – European Association for the Study of the Liver, Amsterdam, The Netherlands, 2017, S500 (Journal of Hepatology).
80. Kumada, H., Suzuki, Y., Ikeda, K., et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59:6 (2014), 2083–2091.
81. Kumada, H., Chayama, K., Rodrigues, L. Jr., et al. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology 62:4 (2015), 1037–1046.
82. Kwo, P., Gitlin, N., Nahass, R., et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in HCV genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology, 2016.
83. Lagace, L., White, P.W., Bousquet, C., et al. In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335. Antimicrob. Agents Chemother. 56:1 (2012), 569–572.
84. Lahser, F.C., Bystol, K., Curry, S., et al. The combination of grazoprevir: a hepatitis C virus (HCV) NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons. Antimicrob. Agents Chemother. 60:5 (2016), 2954–2964.
85. Lam, A.M., Espiritu, C., Bansal, S., et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob. Agents Chemother. 56:6 (2012), 3359–3368.
86. Lawitz, E.J., Gruener, D., Hill, J.M., et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J. Hepatol. 57:1 (2012), 24–31.
87. Lawitz, E., Sulkowski, M., Jacobson, I., et al. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics. Antiviral Res. 99:3 (2013), 214–220.
88. Lawitz, E., Makara, M., Akarca, U.S., et al. Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis. Gastroenterology 149:4 (2015), 971–980 (e1).
89. Lawitz, E., Freilich, B., Link, J., et al. A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus. J. Viral Hepat. 22:12 (2015), 1011–1019.
90. Lawitz, E., Gane, E., Pearlman, B., et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385:9973 (2015), 1075–1086.
91. Lawitz, E., Flamm, S., Yang, J.C., et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvi/sofosbuvir for 24 weeks [Abstract O005]. The International Liver Congress™ 2015, EASL – European Association for the Study of the Liver, Vienna, Austria, 2015, S192 (Journal of Hepatology).
92. ®2015, AASLD – American Association for the Study of Liver Diseases Vol. 62, San Francisco, 2015, 119A (Hepatology).
93. Lawitz, E., Matusow, G., DeJesus, E., et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST -2). Hepatology, 2015.
94. Lawitz, E.J., Dvory-Sobol, H., Doehle, B., et al. Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein. Antimicrob. Agents Chemother., 2016.
95. Lenz, O., Vijgen, L., Berke, J.M., et al. Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435-C202). J. Hepatol. 58:3 (2013), 445–451.
96. Lenz, O., Verbinnen, T., Fevery, B., et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in phase IIb/III studies. J. Hepatol. 62:5 (2015), 1008–1014.
97. Leroy, V., Angus, P., Bronowicki, J.P., et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology 63:5 (2016), 1430–1441.
98. Li, G., De Clercq, E., Current therapy for chronic hepatitis C: the role of direct-acting antivirals. Antiviral Res. 142 (2017), 83–122.
99. Lim, P.J., Gallay, P.A., Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance. Curr. Opin. Virol. 8 (2014), 30–37.
100. Liu, R., Curry, S., McMonagle, P., et al. Susceptibilities of genotype 1a: 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir. Antimicrob. Agents Chemother. 59:11 (2015), 6922–6929.
101. Liverton, N.J., Carroll, S.S., Dimuzio, J., et al. MK-7009: a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob. Agents Chemother. 54:1 (2010), 305–311.
102. Lok, A.S., Gardiner, D.F., Lawitz, E., et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366:3 (2012), 216–224.
103. Lontok, E., Harrington, P., Howe, A., et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology 62:5 (2015), 1623–1632.
104. Ludmerer, S.W., Hirano, T., Black, S., et al. HCV evolutionary genetics of SVR versus virologic failure assessed from the vaniprevir phase III registration trials. Antiviral Res. 130 (2016), 118–129.
105. Manns, M.P., Gane, E., Rodriguez-Torres, M., et al. Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized phase II study. Hepatology 56:3 (2012), 884–893.
106. Manns, M., Pol, S., Jacobson, I.M., et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 384:9954 (2014), 1597–1605.
107. Manns, M., Samuel, D., Gane, E.J., et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect. Dis. 16:6 (2016), 685–697.
108. McCombs, J., Matsuda, T., Tonnu-Mihara, I., et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern. Med. 174:2 (2014), 204–212.
109. McGivern, D.R., Masaki, T., Williford, S., et al. Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors. Gastroenterology 147:2 (2014), 453–462 (e7).
110. McPhee, F.H.D., Zhou, N., Next-Generation sequencing analysis of NS5A and NS5 B minor resistance-associated variants in patients with HCV genotype 3 infection who failed treatment with daclatasvir plus sofosbuvir. poste#171. The International Liver Congress™ 2016, EASL – European Association for the Study of the Liver, Barcelona, Spain, 2016.
111. McPhee, F., Friborg, J., Levine, S., et al. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob. Agents Chemother. 56:7 (2012), 3670–3681.
112. McPhee, F., Hernandez, D., Yu, F., et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology 58:3 (2013), 902–911.
113. McPhee, F., Hernandez, D., Zhou, N., et al. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b. Antivir. Ther. 19:5 (2014), 479–490.
114. McPhee, F., Hernandez, D., Zhou, N., Next-generation sequencing analysis of NS5A and NS5A minor resistance-associated variants in patients with HCV genotype 3 infection who failed treatment with daclatasvir plus sofosbuvi [Abstract FRI-171]. The International Liver Congress™ 2015, EASL – European Association for the Study of the Liver, Vienna, Austria, 2015 (Journal of Hepatology).
115. Messina, J.P., Humphreys, I., Flaxman, A., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61:1 (2015), 77–87.
116. Moreno, C., Hezode, C., Marcellin, P., et al. Efficacy and safety of simeprevir with PegIFN/ribavirin in naive or experienced patients infected with chronic HCV genotype 4. J. Hepatol. 62:5 (2015), 1047–1055.
117. Nelson, D.R., Cooper, J.N., Lalezari, J.P., et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61:4 (2015), 1127–1135.
118. Nettles, J.H., Stanton, R.A., Broyde, J., et al. Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition. J. Med. Chem. 57:23 (2014), 10031–10043.
119. Ng, T., Reisch, T., Middleton, T., et al. ABT-493, a potent HCV NS3/4A protease inhibitor with broad genotype coverage [Abstract 636]. Conference on Retroviruses and Opportunistic Infections (CROI), 2014, Boston, 2014.
120. ®2016, AASLD – American Association for the Study of Liver Diseases. Boston (MA), 2016 (Hepatology).
121. Ng, T., Pilot-Matias, T., Tripathi, R., et al. Analysis of HCV genotype 2 and 3 variants in patients treated with combination therapy of next generation HCV direct-acting antiviral agents ABT-493 and ABT-530 [Abstract THU-240]. The International Liver Congress™ 2016, EASL – European Association for the Study of the Liver, Barcelona, 2016, S409 (Journal of Hepatology).
122. Ng, T., Lu, L., Reisch, T., et al. Resistance selection using glecaprevir and pibrentasvir in replicons of major hepatitis C virus genotypes [Abstract THU-305]. The International Liver Congress™ 2017, EASL – European Association for the Study of the Liver, Amsterdam, The Netherlands, 2017, S324 (Journal of Hepatology).
123. Ogata, N., Alter, H.J., Miller, R.H., Purcell, R.H., Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 88:8 (1991), 3392–3396.
124. Pawlotsky, J.M., Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology 151:1 (2016), 70–86.
125. Pelosi, L.A., Voss, S., Liu, M., Gao, M., Lemm, J.A., Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob. Agents Chemother. 56:10 (2012), 5230–5239.
126. Pilot-Matias, T.J.T.R., Dekhtyar, T., Menon, R.M., Gaultier, I.A., Cohen, D.E., Podsadecki, T.J., Bernstein, B., Collins, C.A., Genotypic and phenotypic characterization of NS3 variants selected in HCV-infected patients treated with ABT-450. The International Liver Congress™ 2011, EASL – European Association for the Study of the Liver, Berlin, Germany, 2011 (Journal of Hepatology).
127. Pilot-Matias, T., Tripathi, R., Cohen, D., et al. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob. Agents Chemother. 59:2 (2015), 988–997.
128. Pilot-Matias, T., Krishnan, P., Schnell, G., et al. Resistance analysis in the MAGELLAN-1 Study (Part 2): Glecaprevir/pibrentasvir therapy in HCV-infected patients who had failed prior DAA regimens containing NS3/4A protease and/or NS5A inhibitors [Abstract SAT-204]. The International Liver Congress™ 2017, EASL – European Association for the Study of the Liver, Amsterdam, The Netherlands, 2017, S708–S709 (Journal of Hepatology).
129. Polaris Observatory HCVC, Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol. Hepatol. 2:3 (2017), 161–176.
130. Poordad, F., Lawitz, E., Kowdley, K.V., et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N. Engl. J. Med. 368:1 (2013), 45–53.
131. Poordad, F., Hezode, C., Trinh, R., et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N. Engl. J. Med. 370:21 (2014), 1973–1982.
132. Poordad, F., Sievert, W., Mollison, L., et al. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 313:17 (2015), 1728–1735.
133. Poordad, F., Landis, C.S., Asatryan, A., et al. High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection. Liver Int. 36:8 (2016), 1125–1132.
134. Poordad, F., Gordon, S.C., Asatryan, A., et al. High efficacy of ABT-493 and ABT-530 in HCV genotype-1 infected patients who have failed direct-acting antiviral-containing regimens: the MAGELLAN-I study [Abstract SAT-157]. The International Liver Congress™ 2016, EASL – European Association for the Study of the Liver, Barcelona, Spain, 2016, S768 (Journal of Hepatology).
135. ®2016, AASLD – American Association for the Study of Liver Diseases, Boston (MA), 2016 (Hepatology).
136. Rockstroh, J.K., Nelson, M., Katlama, C., et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2:8 (2015), e319–e327.
137. Rodriguez-Torres, M., Stoehr, A., Gane, E.J., et al. Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis. Clin. Gastroenterol. Hepatol. 12:6 (2014), 1029–1037 (e5).
138. Romano, K.P., Ali, A., Aydin, C., et al. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog., 8(7), 2012, e1002832.
139. Roth, D., Nelson, D.R., Bruchfeld, A., et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386:10003 (2015), 1537–1545.
140. ®2014, AASLD – American Association for the Study of Liver Diseases, Boston, 2014, 1128A (Hepatology).
141. Sarrazin, C., Lathouwers, E., Peeters, M., et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80 K in genotype 1 patients in the European region. Antiviral Res. 116 (2015), 10–16.
142. Sarrazin, C., Dvory-Sobol, H., Svarovskaia, E.S., et al. The prevalence and the effect of HCV NS5A resistance-associated variants in patients with compensated cirrhosis treated with Ledipasvir/Sofosbuvir ± RBV [Abstract P0773]. The International Liver Congress™ 2015, EASL – European Association for the Study of the Liver, Vienna, Austria, 2015, S620 (Journal of Hepatology).
143. Sarrazin, C., Dvory-Sobol, H., Svarovskaia, E.S., et al. Prevalence of resistance-Associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology, 2016.
144. Sarrazin, C., Cooper, C.L., Manns, M.P., et al. No impact of RASs on the high efficacy of SOF/VEL/VOX for 12 weeks in DAA-experienced patients: an integrated resistance analysis on the POLARIS-1 and POLARIS-4 studies [Abstract THU-248]. The International Liver Congress™ 2017, EASL – European Association for the Study of the Liver, Amsterdam, The Netherlands, 2017, S299 (Journal of Hepatology).
145. Sarrazin, C., The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J. Hepatol. 64:2 (2016), 486–504.
146. Schnell, G., Tripathi, R., Beyer, J., et al. Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir. Antimicrob. Agents Chemother. 59:11 (2015), 6807–6815.
147. ®2016, AASLD – American Association for the Study of Liver Diseases, Boston (MA), 2016, 427A (Hepatology).
148. Serre, S.B., Jensen, S.B., Ghanem, L., et al. Hepatitis C Virus Genotype 1–6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle. Antimicrob. Agents Chemother. 60:6 (2016), 3563–3578.
149. Smith, D.B., Bukh, J., Kuiken, C., et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59:1 (2014), 318–327.
150. Smith, D.B., Bukh, J., Kuiken, C., et al. International Committee on Taxonomy of Viruses (ICTV). HCV Classification. 2018 (Available at: https://talk.ictvonline.org/ictv_wikis/flaviviridae/w/sg_flavi/56/hcv-classification. Accessed 27 November 2017).
151. Soumana, D.I., Ali, A., Schiffer, C.A., Structural analysis of asunaprevir resistance in HCV NS3/4A protease. ACS Chem. Biol. 9:11 (2014), 2485–2490.
152. Soumana, D.I., Kurt Yilmaz, N., Ali, A., Prachanronarong, K.L., Schiffer, C.A., Molecular and dynamic mechanism underlying drug resistance in genotype 3 hepatitis C NS3/4A protease. J. Am. Chem. Soc. 138:36 (2016), 11850–11859.
153. Stirnimann, G., Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. Expert Opin. Pharmacother. 15:17 (2014), 2609–2622.
154. Sulkowski, M.S., Eron, J.J., Wyles, D., et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 313:12 (2015), 1223–1231.
155. Sulkowski, M., Hezode, C., Gerstoft, J., et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385:9973 (2015), 1087–1097.
156. Sulkowski, M., Krishnan, P., Tripathi, R., et al. Effect of baseline resistance-Associated variants on SVR with the 3D regimen plus RBV [Abstract 6LB-3113]. Conference on Retroviruses and Opportunistic Infections (CRO), 2016, Boston, Massachusetts, 2016.
157. Summa, V., Ludmerer, S.W., McCauley, J.A., et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob. Agents Chemother. 56:8 (2012), 4161–4167.
158. Sun, J.H., O'Boyle Ii, D.R., Zhang, Y., et al. Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052. Hepatology 55:6 (2012), 1692–1699.
159. Susser, S., Dietz, J., Vermehren, J., et al. European RAVs database: frequency and characteristics of RAVs in treatment-naive and DAA-experienced patients [Abstract PS007]. The International Liver Congress™ 2016, EASL – European Association for the Study of the Liver, Barcelona, Spain, 2016, S139 (Journal of Hepatology).
160. Suzuki, Y., Ikeda, K., Suzuki, F., et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J. Hepatol. 58:4 (2013), 655–662.
161. Svarovskaia, E.S., Dvory-Sobol, H., Parkin, N., et al. Infrequent development of resistance in genotype 1–6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin. Infect. Dis. 59:12 (2014), 1666–1674.
162. Svarovskaia, E.S., Gane, E., Dvory-Sobol, H., et al. L159F and V321A sofosbuvir-associated hepatitis C virus NS5 B substitutions. J. Infect. Dis. 213:8 (2016), 1240–1247.
163. Taylor, J.G., Appleby, T., Barauskas, O., et al. Preclinical profile of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857 [Abstract P0899]. The International Liver Congress™ 2016, EASL – European Association for the Study of the Liver, Vienna, Austria, 2015, S681 (Journal of Hepatology).
164. Tong, X., Le Pogam, S., Li, L., et al. In vivo emergence of a novel mutant L159F/L320F in the NS5 B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J. Infect. Dis. 209:5 (2014), 668–675.
165. Verbinnen, T., Van Marck, H., Vandenbroucke, I., et al. Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing. J. Virol. 84:21 (2010), 11124–11133.
166. Verbinnen, T., Fevery, B., Vijgen, L., Jacobs, T., De Meyer, S., Lenz, O., In vitro activity of simeprevir against hepatitis C virus genotype 1 clinical isolates and its correlation with NS3 sequence and site-directed mutants. Antimicrob. Agents Chemother. 59:12 (2015), 7548–7557.
167. Vicenti, I., Rosi, A., Saladini, F., et al. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. J. Antimicrob. Chemother. 67:4 (2012), 984–987.
168. Vierling, J., Kugelmas, M., Lawitz, E., et al. Efficacy of an 8-week regimen of grazoprevir plus elbasvir with and without ribavirin in treatment-naive, non-cirrhotic HCV genotype 1b infection. The International Liver Congress™ 2015, EASL – European Association for the Study of the Liver, Vienna, Austria, 2015 (Journal of Hepatology).
169. Vigano, M., Perno, C.F., Craxi, A., AdHoc Working, P., Treatment of Hepatitis C virus infection in Italy: a consensus report from an expert pane. Dig. Liver Dis., 2017.
170. Wang, C., Jia, L., Huang, H., et al. In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob. Agents Chemother. 56:3 (2012), 1588–1590.
171. Wang, C., Valera, L., Jia, L., Kirk, M.J., Gao, M., Fridell, R.A., In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob. Agents Chemother. 57:1 (2013), 611–613.
172. Wang, C., Jia, L., O'Boyle, D.R. 2nd, et al. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1–6: implications for cross-genotype activity. Antimicrob. Agents Chemother. 58:9 (2014), 5155–5163.
173. Wilson, E.M., Kattakuzhy, S., Sidharthan, S., et al. Successful retreatment of chronic HCV genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct-acting antiviral regimens. Clin. Infect. Dis. 62:3 (2016), 280–288.
174. Wong, K.A., Worth, A., Martin, R., et al. Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob. Agents Chemother. 57:12 (2013), 6333–6340.
175. Wyles, D., Thompson, A., Lawitz, E., et al. No impact of RASs on the high efficacy of SOF/VEL/VOX for 8 weeks in DAA-naïve patients: an integrated resistance analysis of the POLARIS-2 and POLARIS-3 studies [Abstract THU-257]. The International Liver Congress™ 2017, EASL – European Association for the Study of the Liver, Amsterdam, The Netherlands, 2017, S303 (Journal of Hepatology).
176. Xu, S., Rajyaguru, S., Hebner, C., et al. In vitro selection of resistance to sofosbuvir in GT 2a, 2b, 3a, 4a, 5a and 6a replicons [Abstract O_01B]. International Workshop on Hepatitis C Resistance and New Compounds, Cambridge, USA, 2013.
177. Zeuzem, S., Jacobson, I.M., Baykal, T., et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 370:17 (2014), 1604–1614.
178. Zeuzem, S., Ghalib, R., Reddy, K.R., et al. Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann. Intern. Med. 163:1 (2015), 1–13.
179. ®2016, AASLD – American Association for the Study of Liver Diseases, Boston (MA), 2016, 59 (Hepatology).
180. Zeuzem, S., Mizokami, M., Pianko, S., et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J. Hepatol., 2017.
181. Zhou, N., Hernandez, D., Ueland, J., et al. NS5A sequence heterogeneity and mechanisms of daclatasvir resistance in hepatitis C virus genotype 4 infection. J. Infect. Dis. 213:2 (2016), 206–215.
182. Zhou, N., Han, Z., Hartman, N.S., et al. High sustained virologic response rates in patients infected with HCV genotype 2 with baseline NS5A polymorphisms treated with daclatasvir-Based regimens [Abstract 234]. The International Liver Congress™ 2016, EASL – European Association for the Study of the Liver, Barcelona, Spain, 2016, S407.